Ace the 2025 CCRA Exam – Get Ready to Rock Your Research Career!

The purpose of a blind review in clinical trials primarily focuses on assessing data after the trial's completion while maintaining objectivity and reducing bias. In a blind review, the individuals assessing the data do not have knowledge of the group assignments (e.g., treatment or control) of the participants. This method helps to minimize any potential biases that might influence the interpretation of the results, ensuring that the conclusions drawn from the data are based solely on the outcome measures and not affected by preconceived ideas about the effectiveness of the treatment being tested.

The other options, while important aspects of clinical trials, do not specifically relate to the unique role of a blind review. For instance, randomizing subject allocation is a method used to ensure that participants are assigned to treatment groups in a manner that mitigates selection bias, but it does not pertain to the review of data. Completing initial data collection refers to gathering data at the beginning of a trial rather than the assessment phase. Ensuring participant confidentiality is a critical ethical aspect across all trials, but it doesn't capture the specific assessment-related function of a blind review.